-- The Company participated in a number of studies that have further elucidated the mechanisms of the estrogen receptor beta pathway, which are the basis of the Company's MF101 and VG101 drug candidates, for menopausal hot flashes and vaginal dryness, respectively.
"The second quarter of the year was again a very productive quarter for Bionovo," said Dr. Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "We have continued to advance our scientific base with several key publications of our discoveries. We have had very productive discussions with our advisors and the FDA, and we are now poised to launch clinical trials for both MF101 and VG101."
"We are very excited at the progress BZL101 is making in the clinical trials for advanced breast cancer. This drug candidate is showing excellent tolerability and safety, and the early signs of significant efficacy," stated Dr. Mary Tagliaferri, M.D., Bionovo's President and CMO.
A full financial report on Form 10-Q is expected to be filed by Tuesday, August 5, 2008.
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and cancer,
markets with significant unmet needs and billions in potential annual
revenue. The company applies its expertise in the biology of menopause and
cancer to design new drugs derived from botanical sources which have novel
mechanisms of action. Based on the results of early and mid-stage clinical
trials, Bionovo believes they have discovered new classes of drug
candidates within their rich pipeline with the potential to be leaders in
their markets. Bionovo is headquartere
|SOURCE Bionovo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved